Navigation Links
Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
Date:1/23/2008

se 1 ascending single dose study in overweight and obese type 2 diabetics (study MSI-1436C-103) under Genaera's obesity IND. Additional phase 1 studies will explore the potential of MSI-1436 in type 2 diabetics and the Company plans to pursue type 2 diabetes as its lead indication in phase 2.

About Trodusquemine (MSI-1436)

Trodusquemine is a centrally and peripherally-acting appetite suppressant and the first highly selective inhibitor of protein tyrosine phosphatase 1B (PTP-1B). PTP-1B is central to controlling the function of both the leptin and insulin pathways. By inhibiting PTP-1B, MSI-1436 is expected to decrease appetite and normalize blood sugar. Trodusquemine has produced consistent, sustainable weight loss in a variety of animal models and appears to overcome metabolic readjustment, which often limits sustained weight loss during caloric restriction. In addition, trodusquemine has shown the ability to reverse co-morbidities associated with obesity such as abnormal glucose metabolism and cholesterol elevation.

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 trial in obesity. In addition, Genaera has a value- driven, fully out-licensed partnership with MedImmune, Inc. for a second core program that is presently undergoing Phase 2 clinical testing in asthma. Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value. For further information, please see our website at http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... SANTA CLARA, Calif. , May 21, ... a game-changing embedded-ultrasound platform, today announced the ... Toolkit that allows complete network-based communications with ... demonstrate its latest embedded-ultrasound technology, including this ... Sao Paulo, Brazil ...
(Date:5/21/2013)... , May 21, 2013 Hurel Corporation ... and microfluidic cell-based assay platforms, today announced the appointment ... DABT to the Company,s Board of Directors. Dr. MacDonald ... of the Schering-Plough Research Institute ("SPRI"), which was the ... acquisition by Merck & Co. in 2009. ...
(Date:5/21/2013)... -- Vasomedical, Inc. (OTC BB: VASO) (the "Company"), a diversified medical ... medical devices and in the domestic sale of diagnostic imaging ... , President and CEO of Vasomedical, Inc. will present at ... 30, 2013 in New York City ... presentation is scheduled to begin at 9:30 a.m. EDT. ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2
... 2012  Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company ... technologies in the field of transplantation therapy for patients ... technology from Yale University. "In the ... Herold and his colleagues at Yale University School of ...
... /PRNewswire-iReach/ -- PharmacyGPO, Inc.,  a ... the United States, today announced a three-year agreement ... (Photo: http://photos.prnewswire.com/prnh/20120507/CG01217 ) ... Smith, a leading national wholesaler, will be the ...
Cached Medicine Technology:Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 3
(Date:5/21/2013)... CINCINNATIUsing the Department of Defense Serum Repository (DoDSR), University ... biomarkers for inflammatory bowel disease (IBD), which could help ... not yet shown symptoms. , This finding, the first ... MD, is being presented via podium presentation by staff ... Disease Week 2013, being held May 18-21 in Orlando, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...
(Date:5/21/2013)... 2013 The American Diabetes Association ( ... the United States of America are affected with peripheral ... great risk of developing peripheral neuropathy which unfortunately makes ... ADA further goes on saying that the disease usually ... 2 million new cases are diagnosed every year in ...
(Date:5/21/2013)... Reporter , , TUESDAY, May 21 (HealthDay News) -- Swollen ... apnea in children, and while removing them did not ... did help them with sleep, behavior and quality of ... a condition that causes abnormal pauses in breathing during ... with the surgery, and those improvements were likely responsible ...
(Date:5/21/2013)... In adults with chronic kidney disease (CKD), cigarette ... progression and transplant failure. Now, a first-of-its-kind study by ... has found a possible similar effect in children with ... , The study of 366 children aged 1 to ... of secondhand smoke exposure in CKD, according to lead ...
Breaking Medicine News(10 mins):Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 3Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 2Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 3
... men enrolled in an active surveillance program for prostate ... fared just as well as men who opted to ... during surveillance showed high-grade cancer. Active surveillance, or ... tumors are considered small, low-grade and at low risk ...
... A psychological intervention program designed for breast cancer patients reduces ... shows. The study is the latest in a series ... program that teaches patients how to cope with the disease ... survival. Researchers at Ohio State,s Comprehensive Cancer Center had ...
... guidelines for best treatment practices are common, they ... to them in clinical practice, according to a ... medicine researchers. In the study, UC associate ... his colleagues used national standards for treatment of ...
... -- City of Hope researchers received approval from the ... first-in-human study of a neural stem cell-based therapy targeting ... tumor. Karen S. Aboody, M.D., associate professor in City ... that developed this treatment strategy. Jana Portnow, M.D., assistant ...
... the University of Cincinnati (UC) and the Cincinnati ... received funding to study the care processes that ... beginning dialysis. Timmy Lee, MD, UC Health ... the study, was awarded the National Kidney Foundation,s ...
... cats have them and whales have some, too. Neurons, those ... our spinal cords to the tips of our toes, paws ... journal Cell , scientists from the Harvard Medical School, ... found a new way by which nerve cells relay information ...
Cached Medicine News:Health News:Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer 2Health News:Intervention program helps breast cancer patients live longer after recurrence 2Health News:Intervention program helps breast cancer patients live longer after recurrence 3Health News:'Knowledge translation' keeps treatment current 2Health News:FDA approves first human neural stem cell clinical trial to treat brain tumors 2Health News:FDA approves first human neural stem cell clinical trial to treat brain tumors 3Health News:New research examines care practices in place for dialysis patients 2
Suture Cutter, straight...
Suture Cutter, 15 Up Curve...
Suture scissor...
...
Medicine Products: